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Foreword
Patients, their families, clinicians and addictions workers are all excited
about the opportunity we now have to cure people of hepatitis C and
eventually to eliminate the disease as a public health threat. However,
this will only be possible if the many services and organisations that are
engaged with people with hepatitis C, and people who are at risk of
contracting hepatitis C, join up their data systems so that people who
are diagnosed can progress quickly and easily to treatment and care.
This sounds simple, but the reality is not straightforward. People may
be diagnosed with hepatitis C at a drugs service, prison, GP practice,
or other outreach service. These organisations will have different IT sys-
tems and processes for sharing diagnoses with Public Health England,
local treatment providers and the local Operational Delivery Network.
Further, interpretations of the new General Data Protection Regulation
(GDPR) and associated Data Protection Act 2018 (DPA18) regulations
have led to confusion in some organisations about data sharing and
consent, even though GDPR and DPA18 do not alter the requirements
of the Health and Social Care (Safety and Quality) Act 2015 for health
and social care organisations to share data that facilitates patient care.
These issues are technical but they are absolutely vital in making the
system work for patients. I am pleased that this report shines a light on
some areas of confusion and misunderstanding, and makes recommen-
dations for a more streamlined, coordinated approach to data sharing.
Whilst many of the insights and recommendations in the report apply
to other areas of healthcare, all of the interviews and discussions that
provide the basis of this report were specifically hepatitis C related.
This report will be useful to any organization involved in hepatitis C test-
ing, treatment or care. I hope it will initiate many to review their data
sharing processes and protocols to ensure these facilitate easy pathways
into treatment and allow for data flows that will benefit every patient.
Dr Emily Finch
Consultant Addiction Psychiatrist, South London and Maudsley
Clinical Director, Addictions Clinical Academic Group
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About the London Joint Working
Group on Hepatitis C
The London Joint Working Group (LJWG) is a group of clinical,
commissioning and patient group experts whose goal is to elim-
inate hepatitis C in drug users and those engaged in drug treat-
ment services in London. The LJWG works with stakeholders to
develop recommendations for improving the rates of hepatitis C
testing, diagnosis, and referral as well as access to specialist as-
sessment and treatment for people who use or have used drugs.
For more information, please visit www.ljwg.org.uk.
Acknowledgements
We would like to thank individuals from the following organisa-
tions for taking time to speak with us regarding the issues de-
scribed in the report: Addaction, CGL, London Joint Working
Group on Hepatitis C, NHS England, Pathway, Public Health Eng-
land, King’s College Hospital, South London and Maudsley NHS
Foundation Trust. We have not listed people by name in order to
preserve their anonymity. This report was funded by AbbVie. Ab-
bVie had no input to the content. This report was written by Dr
Katherine Morley, Dr Emily Finch, and Ms Dee Cunniffe and can
be cited as:
London Joint Working Group on Hepatitis C (2019) Joining the
dots: Linking pathways to hepatitis C diagnosis and treatment
(London: LJWG).
6/25
2
Summary
Hepatitis C is a bloodborne virus that can cause cirrhosis, liver can-
cer and death. However, NICE approved treatments can cure the
virus in around 95% of patients. The responsibility for testing peo-
ple at risk of having hepatitis C, and treating people who are in-
fected, lies across different services including GP practices, drugs
services, prisons, pharmacies and hospitals.
In order to ensure that people at risk are tested, and that people
with hepatitis C can access treatment, effective data sharing path-
ways must be developed between services. This report explores
current barriers and solutions to join the dots and improve data
pathways between testing, treatment and care for hepatitis C pa-
tients.
We identified two major obstacles to effective data sharing in re-
lation to hepatitis C diagnosis and treatment:
1. Confusion about who data can be shared with and under
what circumstances;
2. A lack of computer systems that enable care providers to
easily share patient data.
In particular, we found that obtaining written consent from pa-
tients was often considered the ‘best’, if not the only, basis on
which data could be shared. This is at odds with the Health and
Social Care (Safety and Quality) Act 2015 and General Data Pro-
tection Regulation, which create an obligation to share data for
patient care and provide a legal basis for doing so that does not
require explicit patient consent.
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We made three recommendations to address these obstacles:
1. Development of clear guidance and training for care providers,
particularly those from community drug and alcohol teams,
regarding:
• when explicit patient consent is, and is not, needed to
share data;
• which data can be shared;
• who data can be shared with and under what circum-
stances.
2. Provision of additional support for hepatology outreach, par-
ticularly in community drug and alcohol teams, but poten-
tially also in other community contexts such as pharmacies.
3. Development of informatics solutions that help care providers
to share data, via joint working of Operational Delivery Net-
works and commissioners.
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Motivation &
Approach
3.1Background
3.1.1The Importance of Data Sharing for
Hepatitis C Testing and Treatment
In 2016, the United Kingdom signed up to the World Health Or-
ganization Global Health Sector Strategy on Viral Hepatitis, which
commits participating countries to eliminate hepatitis C as amajor
public health threat by 2030 [1]. This commitment included sign-
ing up to targets of an 80% reduction in incident (new) chronic
hepatitis C (HCV) infections and a 65% reduction in mortality from
hepatitis C by 2030.
In 2018, NHS England took this commitment further by announc-
ing their own target of eliminating hepatitis C by 2025 at the latest,
aiming to become the first country in the world to do so [2].
Current strategies have resulted in increased access to treatment,
but as Public Health England have noted [1]:
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“Our ability to sustain the current increase in numbers ac-cessing treatment will ultimately be limited by our capacityto find and treat those who remain undiagnosed, and to helpthose who are diagnosed but untreated to engage with local
services; only then will we be able to build on the current fall
in avoidable HCV-related deaths.
— Public Health England [1]
Ensuring that people with HCV are identified via testing, and then
able to access treatment requires the involvement ofmultiple care
providers and commissioners. Testing for HCV is primarily con-
ducted by Community Drug and Alcohol Teams (CDATs) as this
service user population has the highest prevalence of hepatitis C
[3,4], but testing is also conducted by General Practitioners (GPs) .
Testing is also conducted in prisons, and has commenced in some
community pharmacies, but this is outside the remit of the current
report.
Figure 3.1 Information sharing pathways between care providers involved in hepatitis C testing
and treatment. The arrows indicate the flow of information to and from the different care providers
that is needed to ensure successful testing and completion of treatment.
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Local authorities are responsible for commissioning HCV testing
in drug services, but the responsibility for testing in GP services
lies with Clinical Commissioning Groups. Additionally, testing for
HCV by CDATs and GPs is usually outsourced to either hospital
or commercial laboratories, although some providers are moving
toward point of care testing using capillary RNA tests and oral
swab testing for antibodies.
Although testing is generally undertaken by CDATs and GPs, the
responsibility for delivery of HCV treatment lies with secondary
care providers and the Operational Delivery Networks (ODNs).
However, NHSEngland is responsible for commissioning the drugs
used to treat HCV on a national basis.
As shown in Figure 3.1, this network of care providers and com-
missioners creates a situation in which all the data needed to pro-
vide HCV treatment does not reside with a single data controller.
Consequently, effective data-sharing strategies are essential in or-
der to provide service users with an efficient and easily navigable
pathway from diagnosis to successful completion of treatment.
3.1.2Data and Data Sharing
Collecting data on patients’ health and sharing that data between
care providers is at the core of optimal patient care. However, the
concept of ‘data’, and thus ‘data sharing’, is interpreted in a vari-
ety of ways by people and organisations involved in the delivery
of health and social care.
This ambiguity, and the resulting anxiety about what sharing is
or is not permissible, means that patient information is often not
shared, even when this would be in the best interests of the pa-
tients [5]. This confusion has been further exacerbated by the in-
troduction of the GDPR. In this report we consider three ‘levels’
of data and associated data sharing:
Aggregated These data consist of anonymised information from many
individuals grouped together, providing a large-scale per-
spective, such as looking at trends in HCV testing rates over
time. These data are only valuable as a whole – there is no
intention or need to examine information from specific in-
dividuals. Identifying information, such as an NHS number,
may be needed to link data fromdifferent sources (e.g. treat-
ment and mortality data) but once this is completed, any
identifying information is removed from the data set. This
type of informationmay be used in health care planning and
policy, but it has no impact on individual treatment.
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Individual These data consist of large amounts of information about
a specific individual, such as their entire GP medical record,
and may contain information about many aspects of an indi-
vidual’s health care (e.g. vaccination records, prescriptions,
test results). It is the data that is used for making decisions
about an individual’s healthcare, and therefore identifying
information such as NHS number, name, and date of birth
need to be retained in order for it to be used effectively.
Item This is a specific piece of information about a specific indi-
vidual, such as the result from a single HCV test. As with in-
dividual data, identifying information needs to be retained
in order for it be used in providing individual care, although
it may also be shared as part of aggregated data collection
(e.g. reporting of HCV testing to PHE). The important aspect
of ‘item’ data is that its scope is very clearly defined. Giving
someone access to this piece of information does not nec-
essarily mean that they have access to an individual’s entire
medical record.
These different types of data are not necessarily subject to the
same regulations regarding consent anddata sharing.What is and
is not permitted under current regulations depends on the type
of data collected, what is it being used for, and who is using it.
3.1.3Regulation of Data Sharing
Regulations regarding data sharing were originally set out in the
Health and Social Care (Safety and Quality) Act 2015, which im-
plemented recommendations from the Caldicott Review [5]. This
specifies that health and adult social care organisations have a le-
gal obligation to share information with each other about patients
under their care in order to provide the best care possible [6].
Attention became more focused on data sharing in 2018 with the
implementation of the European Union General Data Protection
Regulation (GDPR) and the associated Data Protection Act 2018
(DPA18). The DPA18 is designed to provide continuity when the
UK leaves the European Union, but also provides additional pro-
visions not covered by GDPR and therefore both need to be re-
viewed in relation to data sharing [7].
The GDPR and DPA18 set out a range of scenarios for the sharing
and processing of patient data, not all of which require explicit
patient consent. Under the common law duty of confidentiality,
there are two types of consent:
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Explicit This may also be known as express consent, and it is ob-
tained when a patient actively agrees to use and/or disclo-
sure of information, either verbally or in writing.
Implicit This is obtained in circumstances in which it would be rea-
sonable to infer patient agreement with use of the informa-
tion, although a patient has not been directly asked to pro-
vide consent.
Explicit consent may be required to use patient data for research
purposes but is not necessarily required for the use and process-
ing of data for direct care processes.While consent processes and
maintaining patient confidentiality are related, the requirements
are not identical, and the absence of explicit consent does not au-
tomatically mean that data sharing violates patient confidentiality.
The Information Governance Alliance explicitly states [7]:
“Consent is one way to comply with the GDPR, but it isnot the only way, and in many health and social care con-texts obtaining GDPR-compliant consent (which is stricterthan that required for confidentiality) may not be possi-
ble…Organisations should consider the other conditions
available before choosing to rely on consent.
— Information Governance Alliance [7]
Relying on consent as the legal basis for processing data has
practical implications that need to be considered when deciding
whether this is the most appropriate route for an organisation.
Most importantly, the consent obtained must be compliant with
GDPR standards, even if obtained historically. There must also be
a clear mechanism in place for individuals to withdraw their con-
sent. The consequence of this is that if an individual withdraws
their consent, this removes the legal basis for processing personal
data about them [7].
Thus, the focus should not be on consent as the sole legal basis
for sharing and processing patient data. GDPR does not alter the
requirements defined by the Health and Social Care (Safety and
Quality) Act 2015 which place an obligation on health and adult
social care organisations to share data that facilitates patient care.
Fulfilling this obligation does not necessarily require explicit pa-
tient consent.
All publicly funded health and social care organisations are permit-
ted to process patient data in the delivery of care, and for adminis-
trative purposes, under Article 6 andArticle 9 of theGDPR [7]. This
can be done on the basis of implied consent for direct care, and
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also for administrative purposes where it is a reasonable expec-
tation and/or the patient has been informed. This does not pre-
clude discussions about data sharing with patients, and providers
should give patients the opportunity to raise any concerns about
this.
From a regulatory perspective, there are no theoretical obstacles
to data sharing between publicly funded health and social care or-
ganisations; where data sharing specifically relates to patient care
(e.g. sharing of HCV test results or HCV treatment status) there is
in fact an obligation to do this. This definition may appear to pre-
clude sharing of medical information with non-NHS organisations,
but this is not necessarily the case. Medical data can be shared
with non-NHS organisations provided that NHS governance re-
quirements are met, data sharing agreements are in place, and
there is a clear specification of who will have access to which data
and for what purpose.
Duty to Share
Data sharing without explicit patient consent is permissible
under GDPR where sharing is for optimal patient care as this
is a public task and it is potentially problematic for other care
providers not to have this information. There is essentially
a “duty to share” where this is for patient care and when
it could be reasonably expected by patients as part of that
care.
This definition may appear to preclude sharing of medical infor-
mation with non-NHS organisations, but this is not necessarily the
case. Medical data can be shared with non-NHS organisations
provided that NHS governance requirements are met, data shar-
ing agreements are in place, and there is a clear specification of
who will have access to which data and for what purpose.
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3.2Aims and Objectives
Despite the theoretical lack of obstacles, there may bemany prac-
tical obstacles to efficient sharing of data relating to HCV diagno-
sis and treatment due to the multitude of providers involved in
delivering care.
In light of this, the aim of this report was to investigate barriers
and facilitators to data sharing between care providers, and how
this may impact upon case-finding and completion of treatment
for HCV. Specifically, we investigated:
• Data sharing gaps in testing and onward referral for treat-
ment;
• Data sharing between care providers during treatment.
3.3Data Collection
Data were collected during 2018 via note taking during individual
or group interviews undertaken in person or over the telephone
depending on interviewee preference. The interviewees were all
told that the interviews would be confidential and participant con-
tributions would remain anonymous. To avoid identifying partici-
pants in the resulting report, no names of individuals or institu-
tions are used and nodirect quotes are used. Consent was implied
by agreeing to proceed with the interview, and participants were
informed that they could refuse to answer any questions or termi-
nate the interview at any time. Interviews were conducted by in-
terviewers who had no relationship with interviewees, minimising
the potential for any perceived pressure to participate. Individuals
were invited to participate based on their knowledge and/or ex-
perience of different aspects of HCV case-finding, diagnosis, and
treatment.
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Data Sharing
in Practice
4.1SharingwithOther Care Providers
Efficient data sharing is important at all stages of HCV testing
and treatment, particularly because of the risk of treatment disen-
gagement in this population. If referral and initiation of treatment
are not accomplished quickly, the opportunity for treating service
users may be lost.
But even after treatment commences, data sharing is important
as CDAT and GP care providers can help to monitor treatment
progress, assist with meeting treatment requirements, and help
to minimise risk of re-infection after successful completion.
Currently, the strategies used for testing, referral, and treatment
for HCV are tailored to local services. While this has many advan-
tages, the unintended consequence is substantial variation in how
information is shared between care providers and how HCV treat-
ment is managed.
We identified two major obstacles to data sharing in HCV treat-
ment: the legal basis on which data are (or are not) shared, and
the system(s) used to share information between care providers.
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“Routinely invoking explicit consent,even when not required, can createthe perception that data can only beshared on this basis.
Basis for Sharing Data
Although the Caldicott Guardians and Information Governance
specialists we interviewed had a clear understanding of the basis
on which data could be shared for different purposes, and when
explicit consent was and was not required, this understanding has
not penetrated all levels of clinical practice.
Amongst those in clinical practice therewas confusion about when,
and with whom, individual patient records or specific items of in-
formation about a patient could be shared.
Confusion over what is permissible without consent, or with only
implied consent, has resulted in variation between organisations
in how the guidance on information sharing is interpreted.
This has created a focus on obtaining explicit consent for data
sharing as this is the only scenario that has consensus across care
providers. For example, one third sector organisation has imple-
mented a model in which explicit consent is sought from all ser-
vice users for processing data and sharing this information with
other care organisations such as ODNs.
While taking the explicit consent approach circumvents potential
disagreements over data sharing, provided the data are being
shared as part of clinical care or in administrative work that sup-
ports patient care, this is not necessary under GDPR. Even when
an organisation is third sector, rather than part of the NHS, pro-
vided that organisation has the same standard of information gov-
ernance and a data sharing agreement in place, sharing data with
NHS organisations is possible.
The experts we interviewed underlined the importance of consid-
ering models other than explicit consent, particularly in situations
that would result in care providers seeking explicit consent for
something that needs to be done as part of clinical practice re-
gardless.
Routinely invoking explicit consent, even when not required, can
create the perception that data can only be shared on this basis.
Consequently, rather than making data sharing easier, explicit
consent may create barriers if people believe that all the require-
ments for consent under GDPR need to be met before even a
single item of patient data can be shared.
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1. An electronic medical record is a
a computerised version of clinical
notes, test results, and other pa-
tient information. There are many
different types of software that
can be used to store this informa-
tion in a secure, electronic format.
Figure 4.1 Models of information
sharing in Community Drug and
Alcohol Teams. In A, data sharing
depends on direct contact (written or
spoken) with a central staff member.
In B the central staff member still ag-
gregates information from multiple
providers, but it is obtained via EMR
not direct contact.
“The use of outreach staff does notnecessarily resolve issues relating todata sharing between care providersand can, in fact, exacerbate them
Methods for Sharing Data
All the care providers we interviewed had their own electronic
medical record (EMR) 1 system in place, but the specific system for
storing, accessing, and updating these records varies even within
sectors.
More specifically, the EMR systems used by CDATs, GPs, and hos-
pitals all differ, and even CDATs working under the same umbrella
organisation may not currently use the same EMR system. Data
are not usually shared automatically between these systems. For
example, information entered into the EMR system in a hepatol-
ogy department about a service user’s test results or treatment
generally will not automatically appear in the EMR of their CDAT
team.
We found that CDATs and GPs used approaches to overcoming
these obstacles that fit into two broad categories: personal con-
tacts and outreach staff (scenarios A and B respectively in Figure
4.1). In situations where data sharing is based on personal con-
tacts, the responsibility of obtaining treatment updates usually
falls to the keyworker, nurse, or GPwho originally initiated the test-
ing and referral. BothGPs andCDAT staff in this situation are likely
to be reliant on receiving written updates from secondary care
regarding HCV treatment progress. If feedback is not received,
this must then be sought either via written or telephone follow-
up. Failing that, providers must rely on reports from service users
themselves.
Some CDATs had an outreach nurse from hepatology on-site to
deliver both HCV testing and treatment in clinics. Despite the
complexities involved in delivering prescribed medicine in this
context, there was a general consensus that this was an optimal
model for HCV care. However, the use of outreach staff does not
necessarily resolve issues relating to data sharing between care
providers and can, in fact, exacerbate them. Because the differ-
ent EMR systems are not compatible, outreach staff must dupli-
cate data across multiple EMR systems to keep all records up-to-
date and ensure all relevant patient information is shared across
care providers. As well as being time-consuming, this introduces
greater potential for inadvertent errors or incomplete data.
In some ODNs, care providers do have access to a shared system
that integrates EMR information from primary and secondary care
in the local area, which can help facilitate sharing of individual pa-
tient data. However, in some areas this system is “read-only” so
information from the shared system is not used to automatically
update the EMR data held by CDATs, GPs, or secondary care. Ad-
ditionally, these shared local records are generally only available
to NHS providers, and so are not available to non-NHS CDATs.
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4.2Sharing with Patients
Successful HCV treatment starts with sharing information with ser-
vice users about their HCV infection risk. We found that the ap-
proach to offering testing and the types of testing offered varied
between care providers. In the majority of CDAT services, HCV
testing was offered to all service users, and potentially their part-
ners and family members regardless of whether or not drug in-
jection was disclosed. Other providers only targeted those with
known risk factors. While this economical approach is suitable for
primary care, where the prevalence of HCV is expected to be low,
in CDATs this risks missing HCV cases as service users may be ret-
icent to disclose injecting behaviour.
A key source of variation between care providers was the type of
testing offered, which has a substantial impact on the timeframe
between initial testing and sharing information with services users
regarding their HCV status. Some services use dried blood spots
(DBS) for testing and automatically request reflex testing. Others,
including primary care, use venous blood samples, often without
reflex testing, which may require follow-up blood samples to con-
firm the results and leads to a delay in sharing final test results
with users.
There is a move by some providers to finger-prick testing and use
of the Cepheid GeneXpert system, which provides results in hours
rather than days. Reducing the timeframe in which service users
are given this information is likely to have a substantial positive
impact on treatment uptake.
4.3Sharing Nationally
We found that responsibility for sharing data between different
organisations, and what can and/or should be shared at a national
level has been a source of confusion for many care providers. In
particular, sending data to, and receiving data from, Public Health
England (PHE) was a key focus.
While the legal responsibility to report HCV test results to PHEwas
well understood by care providers, there was substantial past and
present confusion around whether the responsibility for sharing
these data lay with the person requesting the HCV test, or the
laboratory conducting the HCV test.
There were multiple calls for better data sharing processes be-
tween PHE, ODNs, and care providers. Both care providers and
PHE have been working with laboratories to improve or imple-
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ment reporting systems and ensure PHE receives all the relevant
data. However, ODNs also expressed concern that they were not
receiving data on new HCV diagnoses and felt that either report-
ing pathways for PHE should also be harnessed to provide the
same data to ODNs, or PHE should provide these data to ODNs.
There was also a desire for the information PHE holds on individ-
uals who have tested positive but not received treatment to be
provided toODNs for follow-up; this was addressed over the time
period this report was conducted and these data are now being
fed back to ODNs with initial re-contact being facilitated by GPs
[8].
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Conclusions
We found that the twomajor obstacles to effective data sharing in
relation to HCV diagnosis and treatment were: (i) confusion over
the legal basis for sharing patient data; (ii) the lack of informatics
solutions for sharing data between care providers.
Explicit consent is just one mechanism by which care providers
are permitted to share data, and it is not always the most appro-
priate choice. The GDPR has specific allowances for sharing data
as part of clinical practice, both in terms of delivering care and
administrative work, that do not require explicit consent.
While this is well understood by Caldicott Guardians and Informa-
tionGovernance professionals, these provisions are not clear to all
those delivering clinical care. This lack of broader understanding,
and differences in interpretation of information sharing guidance
between organisations, present important barriers to data sharing
and thus to delivery of optimal HCV testing and treatment.
Data sharing for HCV testing and treatment may require addi-
tional effort due to the substantial involvement of non-NHS organ-
isations in delivery of care. Data sharing with third sector organi-
sations may be facilitated by NHS Honorary Contracts where indi-
viduals require access to specific items of patient information for a
defined reason, for example where volunteers are involved in sup-
porting service users through HCV testing and/or treatment. How-
ever, where organisations need access to large amounts of data
held on individuals, data sharing agreements will still be needed.
Even when the legal basis for data sharing has been agreed be-
tween care providers, the absence of informatics solutions that
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bridge sectors (e.g. primary and secondary care) presents a ma-
jor technical barrier. There are lots of local strategies for sharing
data, but the majority either: (i) rely on individuals and personal
relationships, which presents high risk of failure and/or (ii) require
duplication of effort to ensure multiple systems are up-to-date as
information is not centralised.
Informatics barriers are not a problem that is specific to the treat-
ment of HCV; this is a problem across the health care system. A
large-scale plan for implementing an EMR system that crosses in-
stitutional barriers is needed as this is a key rate-limiting step in
treatment initiation and successful completion. However, such a
system will take substantial time to become available and local
solutions will be needed in the interim. There are some exam-
ples, such as the Pathway Homeless teams [9], in which systems
from one part of the NHS (in this case, the general practice sys-
tem EMIS), have been used in other parts of the NHS and third
sector organisations, but the applicability depends on clinical re-
quirements.
In addition to the two major obstacles to HCV testing and treat-
ment discussed above, the following obstacles and issues came
up as themes in our interviews:
Timeframe to HCV+ result and treatment Shortening time from testing to result delivery is particu-
larly important for CDAT service users where the window
of opportunity for engagement may be short. DBS with re-
flex testing or Cepheid testing, which have comparatively
short turn-around times, may be the best testing options in
this context. Even with faster testing, there can be delays
of weeks or months before treatment commences; there is
broad support for outreach treatment, in addition to testing,
in CDATS, GPs, and other contexts such as pharmacies.
Responsibility for case-finding versus testing Although ODNs are responsible for case finding, identifica-
tion of cases for treatment generally occurs in CDATs and
GPs.While HCV testing is viewed as important by these care
providers, it is not their primary focus. In CDATs this is just
one part of clinical responsibilities for services already deal-
ing with substantial financial constraints; child protection
and mortality are more immediate risks and thus higher pri-
ority. Having outreach hepatology nurses can help substan-
tially with this, and providing this type of support needs to
be viewed as a priority. Testing and treating in other commu-
nity contexts, such as community pharmacies, also needs to
be considered. In primary care, there is limited professional
training around HCV, so additional education and aware-
ness campaigns may help to support case-finding.
Reporting requirements Services need to ensure that either they or the laboratory
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share HCV+ test results with the ODNs – there is the poten-
tial to harness systems used for PHE reporting to achieve
this where they are already in place. There is also potential
for PHE to provide this information to ODNs, in line with
what is taking place as part of the re-contact exercise.
5.1Recommendations
In light of the findings from this report, we make three recom-
mendations for potential strategies to overcome the obstacles we
have identified.
Obstacle Recommendation
Lack of clarity regarding shar-
ing patient data under GDPR
Clear guidance and training for care providers, particularly
CDATs, regarding:
• when explicit consent is, and is not, necessary for data
sharing;
• which data can be shared;
• who data can be shared with, and under what circum-
stances.
This could be provided by ODNs and/or PHE.
Lack of informatics to facili-
tate data sharing
ODNs and commissioners should to work together to find
informatics solutions to facilitate data sharing between local
care providers, including third sector organisations where
relevant.
Lack of resources to support
HCV testing and treatment
Additional support for hepatology outreach, particularly in
CDATs but potentially also in other contexts such as phar-
macies.
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